Law360, New York (May 23, 2005, 12:00 AM ET) -- A U.K. court has denied a motion by U.S. drug maker Insmed Inc. and its contract manufacturer, Avecia Group PLC, for summary judgment in Tercica’s and Genentech’s patent infringement lawsuit against Insmed.
The court also denied a motion by Insmed and Avecia that attacked the validity of the patent protecting a Genentech growth hormone therapy that Tercica has licensed, the company said.
As is usual in such cases in the U.K., the court ordered Insmed and Avecia to pay legal fees incurred by Tercica and partner...
U.K. Court Refuses To Dismiss Patent Suit Over Growth Hormone
To view the full article, take a free trial now.
